Skip to main content

Table 2 ΔFMD

From: Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

 

Dapagliflozin group

Metformin group

P value

FMD (%)

 FAS population

  Baseline

4.80 ± 1.86 (37)

5.37 ± 2.95 (37)

0.33

  Week 16

5.66 ± 2.12 (37)

5.18 ± 2.09 (37)

0.33

  Change

0.85 ± 2.71 (37)

−0.19 ± 2.51 (37)

0.09

  P value within group

0.06

0.65

 

 Subpopulation: HbA1c at baseline <7.0%

  Baseline

4.72 ± 1.88 (24)

4.88 ± 2.76 (20)

0.83

  Week 16

5.47 ± 2.42 (24)

5.33 ± 2.23 (20)

0.85

  Change

0.75 ± 2.82 (24)

0.45 ± 2.48 (20)

0.71

  P value within group

0.21

0.43

 

 Subpopulation: HbA1c at baseline ≥7.0%

  Baseline

4.95 ± 1.91 (13)

5.94 ± 3.14 (17)

0.30

  Week 16

6.01 ± 1.43 (13)

5.01 ± 1.96 (17)

0.12

  Change

1.05 ± 2.59 (13)

−0.94 ± 2.39 (17)

0.041

  P value within group

0.17

0.13

 
  1. Data are mean ± standard deviation (n). P values show results of comparisons between groups by t test. P values within groups are results of paired t test
  2. FAS full analysis set. See Table 1 for other abbreviations